West Pharmaceutical Services (NYSE:WST) Issues FY 2024 Earnings Guidance

West Pharmaceutical Services (NYSE:WST) issued an update on its FY 2024 earnings guidance on Thursday morning. The company provided earnings per share guidance of 6.350-6.650 for the period, compared to the consensus earnings per share estimate of 7.740. The company issued revenue guidance of $2.9 billion-$2.9 billion, compared to the consensus revenue estimate of $3.0 billion.

West Pharmaceutical Services Trading Up 2.8 %

NYSE:WST traded up $7.63 during trading hours on Friday, reaching $284.79. 1,190,411 shares of the company were exchanged, compared to its average volume of 563,505. The company has a debt-to-equity ratio of 0.03, a current ratio of 2.61 and a quick ratio of 1.95. The firm has a market cap of $20.74 billion, a price-to-earnings ratio of 37.57, a PEG ratio of 5.75 and a beta of 1.00. West Pharmaceutical Services has a 52-week low of $265.00 and a 52-week high of $415.73. The stock has a 50 day simple moving average of $324.09 and a 200 day simple moving average of $355.75.

West Pharmaceutical Services (NYSE:WST) last posted its quarterly earnings results on Thursday, July 25th. The medical instruments supplier reported $1.52 earnings per share for the quarter, missing analysts’ consensus estimates of $1.77 by ($0.25). The company had revenue of $702.10 million for the quarter, compared to analysts’ expectations of $729.36 million. West Pharmaceutical Services had a return on equity of 20.57% and a net margin of 19.42%. The business’s revenue for the quarter was down 6.9% on a year-over-year basis. During the same period in the prior year, the business earned $2.11 EPS. As a group, analysts predict that West Pharmaceutical Services will post 7.76 EPS for the current year.

Insider Activity

In other news, SVP Silji Abraham sold 1,800 shares of the firm’s stock in a transaction on Wednesday, June 12th. The shares were sold at an average price of $330.78, for a total value of $595,404.00. Following the transaction, the senior vice president now owns 2,860 shares of the company’s stock, valued at approximately $946,030.80. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In related news, CEO Eric Mark Green sold 66,000 shares of the firm’s stock in a transaction on Tuesday, May 7th. The shares were sold at an average price of $366.65, for a total transaction of $24,198,900.00. Following the completion of the sale, the chief executive officer now directly owns 152,908 shares of the company’s stock, valued at approximately $56,063,718.20. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, SVP Silji Abraham sold 1,800 shares of the firm’s stock in a transaction on Wednesday, June 12th. The shares were sold at an average price of $330.78, for a total transaction of $595,404.00. Following the sale, the senior vice president now directly owns 2,860 shares of the company’s stock, valued at $946,030.80. The disclosure for this sale can be found here. Insiders own 0.53% of the company’s stock.

About West Pharmaceutical Services

West Pharmaceutical Services, Inc designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products.